Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3278986 | 0.98 | CALCRL (0.62) | CALCRLCYP3A4 | |
| SCHEMBL3278818 | 0.97 | CALCRL (0.62) | CALCRLCYP3A4 | |
| Fumaric Acid SCHEMBL4478815 | 0.96 | CALCRL (0.57) | CALCRLCYP3A4 | |
| Maleic Acid SCHEMBL3282935 | 0.96 | CALCRL (0.57) | CALCRLCYP3A4 | |
| SCHEMBL3278165 | 0.95 | CALCRL (0.63) | CALCRLCYP3A4 | |
| SCHEMBL3281940 | 0.95 | CALCRL (0.60) | CALCRLCYP3A4 | |
| SCHEMBL3285322 | 0.95 | CALCRL (0.56) | CALCRLCYP3A4 | |
| SCHEMBL3278333 | 0.94 | CALCRL (0.60) | CALCRLCYP3A4 | |
| SCHEMBL3278380 | 0.94 | CALCRL (0.60) | CALCRLCYP3A4 | |
| SCHEMBL3284510 | 0.94 | CALCRL (0.56) | CALCRLCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152171-A1 | CGRP Antagonists | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-06-17 | — | — | US | claimed |
| US-7700589-B2 | CGRP antagonists | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-04-20 | — | — | US | claimed |
| US-20080176836-A1 | benzodiazepines; 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylic acid-{(R)-1-(4-amino-3-chloro-5-ethyl-benzyl)-2-[4-(4-methyl-piperazin-1-yl)-piperidin-1-yl]-2-oxo-ethyl}-amide; | RUDOLF KLAUS | 2008-07-24 | — | — | US | claimed |
| US-20080103134-A1 | Use of selected CGRP-antagonists in combination with other antimigraine drugs for the treatment of migraine | RUDOLF KLAUS | 2008-05-01 | — | — | US | claimed |
| US-20070244099-A1 | CGRP Antagonists | RUDOLF KLAUS | 2007-10-18 | — | — | US | claimed |
| US-20060142274-A1 | Use of selected CGRP antagonists for combating menopausal hot flushes | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-29 | — | — | US | claimed |
| US-20060142273-A1 | Use of selected CGRP-antagonists in combination with other antimigraine drugs for the treatment of migraine | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-29 | — | — | US | claimed |
| US-20040132716-A1 | CGRP antagonists | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-07-08 | — | — | US | claimed |
| US-7807666-B2 | CGRP antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-05 | — | — | US | disclosed |
| US-7807666-B2 | CGRP antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-05 | — | — | US | disclosed |
| US-20100152171-A1 | CGRP Antagonists | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-06-17 | — | — | US | disclosed |
| US-20100152171-A1 | CGRP Antagonists | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-06-17 | — | — | US | disclosed |
| US-20100152171-A1 | CGRP Antagonists | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-06-17 | — | — | US | disclosed |
| US-20100152171-A1 | CGRP Antagonists | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-06-17 | — | — | US | disclosed |
| US-20070244099-A1 | CGRP Antagonists | RUDOLF KLAUS | 2007-10-18 | — | — | US | disclosed |
| US-20070244099-A1 | CGRP Antagonists | RUDOLF KLAUS | 2007-10-18 | — | — | US | disclosed |
| US-20060142274-A1 | Use of selected CGRP antagonists for combating menopausal hot flushes | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-29 | — | — | US | disclosed |
| US-20060142273-A1 | Use of selected CGRP-antagonists in combination with other antimigraine drugs for the treatment of migraine | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-29 | — | — | US | disclosed |
| US-20040132716-A1 | CGRP antagonists | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-07-08 | — | — | US | disclosed |
| US-20040132716-A1 | CGRP antagonists | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176836-A1 | benzodiazepines; 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylic acid-{(R)-1-(4-amino-3-chloro-5-ethyl-benzyl)-2-[4-(4-methyl-piperazin-1-yl)-piperidin-1-yl]-2-oxo-ethyl}-amide; | GABRA1, GABRA5, GABRA2 | CALCRL 160/4885CYP3A4 444/4885 |
| US-20070244099-A1 | CGRP Antagonists | CALCRL, OPRL1, CALCA | CALCRL 1/4885CYP3A4 2631/4885 |
| US-20100152171-A1 | CGRP Antagonists | CALCRL, OPRL1, CALCA | CALCRL 1/4885CYP3A4 2631/4885 |
| US-20040132716-A1 | CGRP antagonists | OPRL1, HTR1D, CALCA | CALCRL 4/4885CYP3A4 2140/4885 |
| US-20080103134-A1 | Use of selected CGRP-antagonists in combination with other antimigraine drugs for the treatment of migraine | SCN3A, HTR3A, BDKRB2 | CALCRL 39/4885CYP3A4 3006/4885 |
| US-20060142274-A1 | Use of selected CGRP antagonists for combating menopausal hot flushes | BDKRB2, CALCR, GRPR | CALCRL 4/4885CYP3A4 2927/4885 |
| US-20060142273-A1 | Use of selected CGRP-antagonists in combination with other antimigraine drugs for the treatment of migraine | SCN3A, HTR3A, BDKRB2 | CALCRL 39/4885CYP3A4 3006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.